ORMP Straddle Strategy
ORMP (Oramed Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
ORMP (Oramed Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $184.4M, a trailing P/E of 2.51, a beta of 1.26 versus the broader market, a 52-week range of 1.98-5.01, average daily share volume of 147K, a public-listing history dating back to 2007, approximately 13 full-time employees. These structural characteristics shape how ORMP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.26 places ORMP roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 2.51 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price. ORMP pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a straddle on ORMP?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current ORMP snapshot
As of May 15, 2026, spot at $4.64, ATM IV 54.20%, IV rank 7.72%, expected move 15.54%. The straddle on ORMP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on ORMP specifically: ORMP IV at 54.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ORMP straddle, with a market-implied 1-standard-deviation move of approximately 15.54% (roughly $0.72 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ORMP expiries trade a higher absolute premium for lower per-day decay. Position sizing on ORMP should anchor to the underlying notional of $4.64 per share and to the trader's directional view on ORMP stock.
ORMP straddle setup
The ORMP straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ORMP near $4.64, the first option leg uses a $4.64 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ORMP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ORMP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.64 | N/A |
| Buy 1 | Put | $4.64 | N/A |
ORMP straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
ORMP straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on ORMP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on ORMP
Straddles on ORMP are pure-volatility plays that profit from large moves in either direction; traders typically buy ORMP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
ORMP thesis for this straddle
The market-implied 1-standard-deviation range for ORMP extends from approximately $3.92 on the downside to $5.36 on the upside. A ORMP long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ORMP IV rank near 7.72% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ORMP at 54.20%. As a Healthcare name, ORMP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ORMP-specific events.
ORMP straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ORMP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ORMP alongside the broader basket even when ORMP-specific fundamentals are unchanged. Always rebuild the position from current ORMP chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on ORMP?
- A straddle on ORMP is the straddle strategy applied to ORMP (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ORMP stock trading near $4.64, the strikes shown on this page are snapped to the nearest listed ORMP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ORMP straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ORMP straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 54.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ORMP straddle?
- The breakeven for the ORMP straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ORMP market-implied 1-standard-deviation expected move is approximately 15.54%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on ORMP?
- Straddles on ORMP are pure-volatility plays that profit from large moves in either direction; traders typically buy ORMP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current ORMP implied volatility affect this straddle?
- ORMP ATM IV is at 54.20% with IV rank near 7.72%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.